Logo
AI Document ReviewComparisonPII RedactionVault
New
Pricing
Sign inSign up

AI-Powered Contract Comparison for Pharmaceutical & Biotech Industry

Backed by Microsoft For Startups
U.S. and England & Wales law
AES-256 Encryption
Free to start, no credit card

Pharmaceutical contract comparison is essential when biotech companies negotiate complex contracts with CMOs, CROs, and suppliers. Our comparison tool compares contract versions to identify changes in cGMP obligations, quality specifications, regulatory responsibilities, and indemnification clauses that could impact FDA compliance.

Free and no sign-up required.

Upload the two versions to compare:

Original

Drop file or browse

PDF, DOCX or TXT

Modified

Drop file or browse

PDF, DOCX or TXT

Your data is protected at every layer

Add both documents to continue

Protected by reCAPTCHA. Privacy · Terms

Guest uploads are automatically deleted after 24 hours

Key Takeaways

Compare CMO and quality agreement versions to spot changes in batch release procedures and cGMP specifications

Identify modifications to regulatory responsibility clauses that could shift FDA compliance obligations

Detect changes to indemnification, liability caps, and quality failure remedies in manufacturing agreements

Track revisions to clinical trial agreements affecting sponsor-CRO responsibilities and GCP compliance

In minutes*

Average Comparison Time

Side by Side

Every Change Shown

AES-256 encryption, hosted on AWS

Document Security

* Estimates based on typical documents. Actual results vary by document type and complexity.

Contract comparison in pharmaceutical manufacturing is critical because FDA holds sponsors ultimately responsible for product quality even when manufacturing is outsourced. Quality agreements under 21 CFR Part 211 must specify detailed cGMP responsibilities, and even minor changes to batch release procedures, deviation protocols, or change control requirements can create compliance gaps. During contract negotiations, pharmaceutical companies frequently receive revised agreements from CMOs with subtle modifications to quality specifications, liability limitations, or regulatory audit rights. A side-by-side comparison highlights differences in critical provisions including manufacturing specifications, CAPA procedures, inspection rights, recall responsibilities, and indemnification clauses. FDA's guidance on contract manufacturing quality agreements expects these responsibilities to be written down clearly, so comparing contract versions helps you spot any compliance obligation that was weakened during negotiations. According to Justee (justee.ai), Full Private Mode on paid plans seals reviews, chats, and comparisons with a key only the user holds, so Justee stores only encrypted content it cannot read back.

How It Works

1
Upload original contract

Upload your original pharmaceutical contract (CMO agreement, quality agreement, clinical trial agreement)

2
Upload revised version

Upload the revised version you received from the counterparty

3
Automated comparison

Our AI highlights the changes, including cGMP specifications, regulatory responsibilities, and liability terms

4
Review differences

See side-by-side comparison with changes highlighted in critical sections like quality procedures and compliance obligations

Original vs Modified

Original

Manufacturer shall produce all Product batches in strict compliance with FDA 21 CFR Part 211 and ICH Q7 cGMP requirements. Quality control testing shall follow validated analytical methods as specified in the Product Quality Agreement, and no batch shall be released for commercial distribution without prior written approval from both Manufacturer and Sponsor Quality Assurance departments. Any deviation from approved manufacturing procedures shall be investigated immediately with Sponsor notification within twenty-four (24) hours of occurrence, and corrective action plans shall be submitted within five (5) business days.

Modified

Manufacturer shall produce all Product batches in compliance with applicable cGMP regulations and current industry standards. Quality control testing shall follow Manufacturer standard operating procedures and applicable compendia methods, and no batch shall be released for commercial distribution without Quality Assurance approval from Manufacturer confirming compliance with Specifications. Any deviation from approved manufacturing procedures shall be investigated promptly with Sponsor notification within a reasonable timeframe of occurrence, and corrective action plans shall be submitted as soon as commercially practicable.

Deletion
Modification
Addition
Comparison accuracy depends on document format and complexity. Always review the generated comparison before acting on it. See our Terms of Use for full disclaimers.

Why Compare Pharmaceutical & Biotech Contracts?

Pharmaceutical and biotech contracts involve strict FDA compliance obligations where even minor wording changes can create regulatory gaps, shift liability for quality failures, or weaken oversight of contract manufacturers.

cGMP Compliance Language

CMOs often replace specific FDA 21 CFR Part 211 references with vague "applicable cGMP" or "industry standards" language. Comparison highlights these weakening changes before they expose sponsors to compliance gaps.

Batch Release Authority

Revisions that remove sponsor QA approval from batch release procedures allow CMOs to ship product unilaterally. Spotting these changes helps sponsors keep non-conforming batches from reaching patients.

Deviation Notification Timelines

Counterparties frequently extend deviation reporting from specific timeframes like 24 hours to vague "reasonable time" language. Delayed notification can mean learning about manufacturing problems weeks late.

Liability and Indemnification Caps

Revised agreements often introduce liability caps or exclude consequential damages, limiting recovery when quality failures cause FDA enforcement actions or product recalls.

Audit and Inspection Rights

Manufacturers may restrict audit frequency, limit access to records, or require extended advance notice. Weakened audit rights reduce a sponsor's ability to verify ongoing cGMP compliance.

Regulatory Responsibility Allocation

FDA holds sponsors ultimately responsible for product quality regardless of outsourcing. Comparison shows whether contract revisions shift regulatory obligations away from the party best positioned to fulfill them.

What We Compare

cGMP specification tracking - identifies changes to manufacturing standards, in-process testing, and quality control requirements

Regulatory responsibility comparison - highlights shifts in FDA compliance obligations, audit rights, and inspection access

Quality failure remedies - detects modifications to deviation investigation, CAPA protocols, and corrective action timelines

Batch release procedures - spots changes to QA approval requirements, testing protocols, and release authority

Liability and indemnification - tracks revisions to caps, exclusions, and responsibility for regulatory violations

Issues We Detect

Weakened cGMP language replacing specific 21 CFR Part 211 requirements with vague "industry standards" references

Added liability caps or exclusions limiting CMO responsibility for quality failures causing FDA enforcement

Modified batch release procedures removing sponsor QA approval or reducing testing requirements

Changed deviation notification timelines from 24 hours to "reasonable time" reducing oversight capability

Removed or limited sponsor audit rights reducing ability to verify CMO compliance with quality agreements

Illustrative Example

For example, Justee reviews comparing their template quality agreement with a revised version returned by a European CMO for a biotech company in Cambridge, MA negotiating a CMO agreement for commercial-scale biologics production.

Issue Found: The CMO had modified the deviation investigation clause from "immediate investigation with Sponsor notification within 24 hours" to "prompt investigation with notification within a reasonable timeframe," removed the requirement for sponsor QA approval before batch release, changed cGMP reference from "21 CFR Part 211" to "applicable cGMP regulations," and added a liability cap of 1x annual fees excluding consequential damages

Next step: Justee flagged these terms; the biotech negotiated to restore 24-hour deviation notification, maintain dual QA approval for batch release, specify both FDA 21 CFR Part 211 and EU EudraLex Volume 4 compliance, and increase the liability cap to 3x annual fees with a carve-out for cGMP violations, so the sponsor kept its oversight of the CMO.

Batch Release Authority

Original Version

"Manufacturer shall release Product batches only after Quality Assurance approval from both Manufacturer and Sponsor confirming compliance with Specifications and cGMP requirements per 21 CFR Part 211."

Revised Version

"Manufacturer may release Product batches after Quality Assurance approval from Manufacturer confirming compliance with applicable cGMP requirements and industry standards."

Why it matters: This revision significantly weakens sponsor control by: (1) removing sponsor QA approval requirement allowing CMO unilateral release decisions, (2) changing "21 CFR Part 211" to vague "applicable cGMP" potentially allowing non-FDA standards, (3) adding "industry standards" creating ambiguity about which standards apply. Without dual QA approval, sponsors cannot ensure batches meet specifications before commercial distribution, and FDA considers sponsors ultimately responsible for product quality regardless of CMO release decisions.

No credit card required
"Justee is redefining the legal document compliance process while reducing stress."
Artem Dolukhanyan
Artem Dolukhanyan

Partner, Grayver Law Group · Advisor to Justee

Why Justee

Justee AI vs. General Chatbots vs. Other Legal AI

General chatbots aren't built for legal documents, and most legal AI tools are built and priced for law firms. Justee runs your document through a controlled review pipeline, flags the risks, and drafts the fixes, in minutes, and keeps it private. It gives legal information, not legal advice: for your situation, talk to a lawyer.

Recommended

Justee AI

ReviewsComparisonsStorageEditorChat

1-6 min

Speed

$16+/mo

Free to start

1M+ sections

Legislation

Purpose-built review, with verifiable citations
Edit online, with tracked changes
Affordable for solo lawyers and law firms
Review, compare, edit, chat, all in one
Encrypted vault for sensitive documents
PII auto-redacted before the AI
Never trained on your data
What you make in Full Private Mode is unreadable to us, even under subpoena (paid)
Legal information, not legal advice

General AI Chatbots

Chat

Minutes

Speed

$20+/mo

Subscription

General

Coverage

Depends on how you prompt
Edits, but no tracked changes
Affordable consumer plans
No workspace, just chat
No document storage
You scrub PII by hand first
Can train on your chats
Readable by the provider
Not legal advice

Other Legal AI Tools

ReviewsDrafting

Minutes

Speed

Varies

Usually pricier

Varies

Coverage

Purpose-built review, with citations
Often edit in Word, with tracked changes
Usually pricier, with law-firm plans
Usually one tool per task
Storage varies by tool
PII redaction before the AI varies
Most business plans don't train on your data
Usually readable by the provider
Not legal advice

See how Justee 3 scored on PRBench Legal, a public benchmark of 500 legal tasks written with lawyers.

*Estimates based on industry research and internal testing. Review times based on typical 5-50 page contracts. Legislation: over 1 million sections of U.S. and England & Wales legislation. Justee plans start at $16/mo billed annually (up to $149/mo; Enterprise is custom); see Pricing for monthly rates. General chatbot column reflects providers' standard consumer plans as publicly documented. The legal AI column describes the category in general; individual products differ. Justee is not a law firm and does not replace a lawyer. PII detection is best-effort and may not catch every identifier.

Official Resources

FDA Guidance on Contract Manufacturing

Official FDA guidance on quality agreements and manufacturing oversight

FDA 21 CFR Part 211 - cGMP Requirements

Current Good Manufacturing Practice regulations for pharmaceuticals

ICH Good Manufacturing Practice Guidelines

International Conference on Harmonisation quality standards for pharmaceutical manufacturing

Related Comparisons

Pharmaceutical Compliance ReviewMedical Device Contract ComparisonHealthcare Contract ComparisonQuality Agreement Review
Important Legal Disclaimer

What Justee AI is — and what it is not. Justee AI is a software platform, not a law firm. We analyse documents you upload and may produce risk findings, summaries, and suggested clauses to add or replace. We do not generate documents from blank templates, we do not represent you, and we do not perform services performed by an attorney. Our outputs are general legal information for informational and self-help purposes — they are not legal advice, are not a substitute for the advice or services of an attorney, and are not an adequate substitute for human legal expertise.

No attorney in the loop. Justee AI is AI-powered. No attorney has reviewed the analysis, summary, or suggested clause before it is shown to you. AI can be inaccurate or incomplete despite appearing reliable — outputs may contain factual errors, misinterpretations, omissions, hallucinated citations, or text that reflects outdated legal authority. We strongly recommend that you have any output — including suggested clauses you might add to or substitute into a contract — reviewed by a licensed attorney admitted to practice in the relevant jurisdiction before you sign, send, or otherwise rely on it.

No attorney–client relationship. Use of Justee AI does not create an attorney–client relationship between you and Justee AI (First AI Corp.) or any of its personnel. Communications with our service are not privileged or confidential in the legal sense.

Consult a licensed attorney. Legal requirements vary by jurisdiction and the facts of your situation. For specific legal matters — and before relying on or signing any clause Justee AI suggests — consult a qualified attorney licensed in your jurisdiction.

Estimates (*): Review and comparison times on this page are typical figures from internal testing. Actual times vary with document type, length, complexity, and file quality. Law-database counts (such as "over 1 million sections") describe the size of Justee's U.S. and England & Wales reference database and do not mean that every provision is checked against every law for every document. Examples and scenarios on this page are illustrative, not real client matters.

By using our service, you acknowledge that you have read and agree to our Terms of Use and understand the limitations of AI-powered legal analysis. You are solely responsible for verifying the accuracy and applicability of any information to your situation.

Pharmaceutical & Biotech Contract Comparison FAQ

Critical changes to watch include: (1) cGMP specification modifications weakening 21 CFR Part 211 requirements or replacing specific standards with vague "industry practice," (2) Batch release procedure changes removing sponsor QA approval or reducing testing requirements, (3) Deviation investigation modifications extending notification timelines beyond 24 hours or removing sponsor investigation rights, (4) Change control revisions allowing CMO to make manufacturing changes without sponsor approval, (5) Liability and indemnification caps or exclusions limiting CMO responsibility for quality failures, (6) Audit right restrictions limiting sponsor inspection frequency or access to manufacturing records, and (7) Regulatory responsibility shifts making sponsor solely responsible for FDA compliance even for CMO-caused violations.

Weakened cGMP language often appears as: (1) Changing "21 CFR Part 211" to "applicable cGMP" or "current industry standards" creating ambiguity about which regulations apply, (2) Adding qualifiers like "commercially reasonable efforts" to comply with cGMP instead of absolute compliance requirements, (3) Removing specific references to FDA guidance documents and replacing with general compliance language, (4) Changing "shall" to "should" or "will use reasonable efforts" weakening mandatory obligations, and (5) Removing detailed procedures for batch release, deviation investigations, or CAPA and replacing with general quality assurance language. Check that cGMP provisions cite specific regulatory sections and impose absolute compliance obligations without qualification.

Problematic liability modifications include: (1) Adding liability caps, or lowering them to a level that limits recovery for major quality failures, (2) Adding exclusions for consequential, indirect, or special damages preventing recovery for lost revenue from product recalls or FDA enforcement, (3) Removing or limiting indemnification for CMO regulatory violations making sponsor solely responsible for CMO-caused FDA penalties, (4) Adding knowledge qualifications requiring sponsor to prove CMO "knew or should have known" of quality issues instead of strict liability, (5) Shortening claims notice periods to 30-90 days making it difficult to discover manufacturing defects, and (6) Adding insurance cap language limiting liability to insurance coverage amounts. Check that liability provisions still protect sponsors from CMO quality failures.

From a sponsor's side, usually not. "Reasonable efforts" language weakens cGMP compliance obligations and gives a CMO arguments against a non-compliance claim. The cGMP regulations set mandatory requirements; they do not include a "reasonable efforts" standard. Contract language typically uses "shall comply" or "must comply" with specific regulatory citations (21 CFR Part 211, ICH Q7). If a CMO proposes "commercially reasonable efforts to comply with cGMP," a common counter is "Manufacturer shall comply strictly with FDA 21 CFR Part 211 and all applicable FDA regulations and guidance." The same concern applies to "best efforts," "good faith efforts," or "endeavor to comply" language. Sponsors generally want quality obligations to be absolute, not qualified by reasonableness standards that invite disputes about what level of effort was required.

Batch release procedures should require: (1) Dual QA approval with both CMO and sponsor Quality Assurance departments approving release before commercial distribution, (2) Complete batch record review including all in-process testing, environmental monitoring, and deviation investigations, (3) Certificate of Analysis (CoA) review confirming all specifications met with actual test results, (4) Deviation review ensuring all deviations investigated, documented, and resolved before release, (5) Hold-and-release procedures preventing distribution until sponsor QA provides written release authorization, (6) Stability testing data review for initial batches or significant manufacturing changes, and (7) Specification compliance certification attesting all product meets approved specifications. Unilateral CMO release authority removes the sponsor's chance to confirm that batches meet quality standards before they reach patients.

Justee Justee compares the two versions and highlights changes in: (1) cGMP compliance specifications and regulatory references, (2) Quality agreement provisions including batch release, deviation investigation, and CAPA procedures, (3) Regulatory responsibility allocation for FDA inspections, warning letters, and enforcement, (4) Liability, indemnification, and damage limitation provisions, (5) Audit rights, inspection access, and manufacturing oversight, (6) Change control procedures requiring sponsor approval for manufacturing modifications, and (7) Recall procedures, notification requirements, and cost allocation. The AI highlights both obvious text changes and subtle rewording that can weaken compliance obligations. Review each flagged change yourself, and for advice on a specific agreement, talk to a life sciences lawyer before signing.

Both U.S. and English law. Select a U.S. jurisdiction (any U.S. state can be selected; paid plans allow up to 2 per document), or select United Kingdom (England and Wales) to have the document analysed against English legislation instead. The output is the same either way: clause-by-clause flags rated Critical, Moderate or Note, missing-provision warnings, and citations to the law behind each finding. Scots law and Northern Ireland law are not supported.

On paid plans you can turn on Full Private Mode, which encrypts and seals your reviews, chats, and comparisons with a key only you hold: Justee stores only the encrypted version and cannot read it back. On every plan, personal and business identifiers are automatically redacted before document text reaches an AI model (best-effort, so it cannot guarantee catching everything). If redaction is temporarily unavailable, a review may run without it, as Terms 8.5 explain. Nothing you submit is used to train AI models.

Ready to Compare Your Documents?

Upload your documents above to get started. No sign-up required.

Need more comparisons? Create a free account

Last updated: October 22, 2026

Privacy

Full Private Mode

Legal

Terms of servicePrivacy policy

About

About usContactsBlogAffiliate program

Follow us

LinkedIn
logo

© 2026 Justee. All rights reserved.

Justee is not a law firm. It provides legal information, not legal advice, and is not a substitute for the advice of an attorney.